Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.37 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.33 |
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | PTGFR | P43088 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7835398 | 1.00 | TACR1 (0.38) | TACR1SIRT1FUCA1SLC15A1AGTR2 | |
| SCHEMBL6052769 | 1.00 | TACR1 (0.38) | TACR1SIRT1FUCA1SLC15A1AGTR2 | |
| SCHEMBL7528040 | 1.00 | TACR1 (0.38) | TACR1SIRT1FUCA1SLC15A1AGTR2 | |
| SCHEMBL2675548 | 1.00 | TACR1 (0.38) | TACR1SIRT1FUCA1SLC15A1AGTR2 | |
| SCHEMBL6053005 | 0.93 | TACR1 (0.40) | TACR1SIRT1FUCA1SLC15A1AGTR2 | |
| SCHEMBL6494918 | 0.93 | TACR1 (0.40) | TACR1SIRT1FUCA1SLC15A1AGTR2 | |
| SCHEMBL6053036 | 0.83 | TACR1 (0.48) | TACR1SIRT1GAADPP4ACE | |
| SCHEMBL7531133 | 0.81 | TACR1 (0.44) | TACR1DPP4ACE | |
| SCHEMBL6052770 | 0.80 | FUCA1 (0.40) | TACR1SIRT1FUCA1GBA1GAA | |
| SCHEMBL6052771 | 0.80 | FUCA1 (0.40) | TACR1SIRT1FUCA1GBA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699884-B2 | ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. | PHARMACIA CORPORATION | 2004-03-02 | — | — | US | claimed |
| US-6555569-B2 | Especially for treatment of Chlamydia pneumoniae | PFIZER INC. | 2003-04-29 | — | — | US | claimed |
| US-20020123513-A1 | Use of glycogen phosphorylase inhibitors to inhibit tumor growth | PFIZER PRODUCTS INC. | 2002-09-05 | — | — | US | claimed |
| EP-1177791-A2 | Use of glycogen phosphorylase inhibitors to inhibit tumor growth | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| US-20010046985-A1 | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection | SUTCLIFFE JOYCE A (US) | 2001-11-29 | — | — | US | claimed |
| EP-1149580-A1 | Use of heteroaryl substituted N-(Indole-2-Carbonyl-) amides for the manufacture of a medicament for the treatment of infection | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | claimed |
| EP-0846464-A2 | Use of glycogen phosphorylase inhibitor for reducing non-cardiac tissue damage resulting from ischemia | PFIZER INC. (US) | 1998-06-10 | — | — | EP | claimed |
| US-20150050371-A1 | Extract Formulations of Rhodamnia Cinerea And Uses Thereof | BIOTROPICS MALAYSIA BERHAD (MY) | 2015-02-19 | — | — | US | disclosed |
| WO-2013133685-A1 | EXTRACT FORMULATIONS OF RHODAMNIA CINEREA AND USES THEREOF | BIOTROPICS MALAYSIA BERHAD (MY) | 2013-09-12 | — | — | WO | disclosed |
| EP-1636224-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LTD (GB) | 2010-07-14 | — | — | EP | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-7405210-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | OSI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
| US-20010046958-A1 | Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2001-11-29 | — | — | US | disclosed |
| US-20010046985-A1 | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection | SUTCLIFFE JOYCE A (US) | 2001-11-29 | — | — | US | disclosed |
| EP-1157695-A1 | Method of treating obesity using a neurotensin receptor ligand | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | disclosed |
| EP-1149580-A1 | Use of heteroaryl substituted N-(Indole-2-Carbonyl-) amides for the manufacture of a medicament for the treatment of infection | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-1127882-A1 | Tetrazole compounds as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1125580-A2 | Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-0846464-A2 | Use of glycogen phosphorylase inhibitor for reducing non-cardiac tissue damage resulting from ischemia | PFIZER INC. (US) | 1998-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010046985-A1 | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection | PYGL, PYGM, PYGB | TACR1 4321/4885SIRT1 1143/4885FUCA1 60/4885 |
| US-20010046958-A1 | Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors | PYGM, GYS1, PYGL | TACR1 4022/4885SIRT1 1769/4885FUCA1 419/4885 |
| US-20020123513-A1 | Use of glycogen phosphorylase inhibitors to inhibit tumor growth | PYGL, PYGM, G6PC1 | TACR1 4450/4885SIRT1 2564/4885FUCA1 110/4885 |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | PYGL, PYGM, PYGB | TACR1 3420/4885SIRT1 778/4885FUCA1 1960/4885 |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | TACR1 3420/4885SIRT1 778/4885FUCA1 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.